Isolation and Identification of Fungi from Wounds and Burns of Human and Farm Animals
Article Sidebar
Main Article Content
Abstract
This study was conducted to isolate and identify the fungi that infect burn wounds in humans and
acquired wounds or wounds resulted from surgical operation in farm animals. A total of 110 cotton
swabs, 60 cotton swabs were collected from wounds to 6 kinds of farm animals, which include 10
swabs for each type of these animals (cattle, sheep, goats, cats, dogs, donkeys). As well as 50 swabs
were collected from human burns. All these samples were cultured onto Sabouraud dextrose agar
(oxoid, England) to detect fungi in wounds of humans and animals in Baghdad city.Identification of
Yeasts were done by use RapID™ Yeast Plus System (remel, USA), While the Identification of
moulds were done in the Central Public Health Laboratory, depending on the macroscopic appearance
of the colony and microscopic examination. Growth was positive for 49 (81.66%) cases of the total
60 wounds swabs. Which detect etiological fungi that infect wounds of animals were as follows:
Trichosporon beigelii 6 (10%), Candida parapsilosis 2 (3.33%), Yarrowia lipolytica 1 (1.66%),
prototheca zopfii 1 (1.66%), Candida lambica 1 (1.66%), Aspergillus flavus 7 ( 11.66%), Penicillum
6 (10%), Rhizopus 6 (10%) , Aspergillus niger 5 ( 8.33%), Trichophyton rubrum 5 (8.33%), Mucor
5 (8.33%), Alternaria 4 (6.66%), Aspergillus fumigates 2 (3.33%), Aspergillus terrus 2 (3.33%),
Epidermophyton floccosum 2 (3.33%) , Helminthosporium 1 (1.66%), Geotricum 1 (1.66%),
Fusarium 1 (1.66%). As well as the growth was positive for 37 (74%) cases of 50 swabs taken from
the burns in humans. They were found that the causative agent of burns wounds in humans were:
Candida albicans 3 (6%), Yarrowia lipolytica 2 (4%), Trichosporon beigelii 1 (2%), Cryptococcus
albidus 1 (2%), Prototheca zopfii 1 (2%), Candida guilliermondii 1 (2%), Aspergillus niger 6
(12%), Aspergillus flavus 4 (8%), Aspergillus fumigates 3 (6%), Penicillum 5 (10%),
Rhizopus 3 (6%), Alternaria 2(4%), Fusarium 1 (2%), Trichophyton rubrum 1 (2%), Mucor 1 (2%),
Helminthosporium 1 (2%), Geotrichum 1 (2%). Drug susceptibility test was done by using disc
diffusion method onto Muller Hinton agar, in this study use 5 types of antifungal disc were used
(Amphotrecin B, Nystatin, Fluconazole, Ketoconazole, Itraconazole).
Downloads
Article Details
How to Cite
References
Singleton, P. and Sainsbury, D. (1978). Dictionary of medical microbiology. Churchill Livingstone Edinburgh, PP: 26-30.
Torpy, J.M.; Alison, B. and Richard M.G. (2005).Surgical wound infections. JAMA, 294:21-22.
Collier, M. (2003). Understanding wound inflammation. Nurs. Times, 99(25):63-64.
Calvin, M. (1998). Cutaneous wound repair. Wounds, 10(1):12-32.
Bowler, P.; Duerden, B. and Armstrong, D. (2001).Wound microbiology and associated approaches to wound management. Clin. Microbiol. Rev.,14(2):244-269.
Gus Gunzalez Bronze, M.S.; Drevets, D.A.; Glatt, A.; Mylonakis, E. and Burke, A.C. (2006). Surgical Wound Infection. http://www.emedicine.com/MED/topic1929.htm .
Guthrie, C. and Fink, G.R. (1991). Guide to yeast genetics and molecular biology. In Methods in Enzymology. Vol. 194, Academic Press, San
Diego, PP:1–932
Duguid, J.P.; Marmion, B.P. and Swain, R.H.(1984). Pathogenic Fungi. In: Medical Microbiology. Part 4, Ch. 5, Mackie and McCartey
(ed.) Vol. 1., PP: 541-547 .
Arther, G. J.; Ziegler, R. J.; Lukasewyez, Q.A. and Hawely, L.B. (2004). Microbiocal Infection.
th (ed.): Churchill livibiology and immunology.3rd edition. Lippincot Williams and Watkins,Philadelphia., PP: 169-195.
Becker, W.K.; Cioffi, W,G.; McManus, A.T.;Kim, S.H.; McManus, W.F.; Mason, A.D. andPruitt, B.A. (1991). Fungal burn wound
infection. A 10-year experience. Arch Surg.,126(1):44-48.
Doezi, I.; Dosa, E.; Hasdue and Nagy, E.,(2002). Aetiology and antifungal susceptibility of yeast blood stream infections in a hungarian
University Hospital between 1996 and 2000. J. Med. Microbiol., 51:677-681.
Mousa, H.A. (1999). Fungal infection of burn wounds in patients with open and occlusive treatment methods. Eastern Mediterranean
Health J., 5(2):333-336.
AI-Akayleh, A.T. (1999). Invasive burn woundinfection. Annals of Burns and Fire Disasters -
XII.http://www.medbc.com /annals/review/vol_12/num_4/text/vol12n4p204.htm.
Pfaller, M.A.; Diekemia, D.J.; Mendez, M.;Kibbler, C.; Erzsebet, P.; Chang, S.H.; Gibbs, D.L. and Newell, V.A. (2006). Candida
guilliermondii, an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends
from the ARTEMIS DISK Antifungal Surveillance Program. J. Clin. Microbiol., 44(10):3551-3556.
Cornelia, L.F. and Astrid, M. (2007): Human Protothecosis. Clinical Microbiology Reviews, 20(2):230–242.
Jan, W. M.; van der Linden, S.; Kampinga, A.;Bart, J.A.; Eva, M.R.; Debets-Ossenkopp, Y.J.;Ed, J.K.; Van Tiel, F.H.; Melchers, W.J.G. and
Verweij, P.E. (2009). Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands. Emerging Infectious Diseases,
:1846-1854.
Vitale, R.G.; de Hoog, G.S.; Schwarz, P.;Dannaoui, E.; Deng, S.; Machouart, M.; Voigt, K.; van de Sande, W.W.; Dolatabadi, S.; Meis,
J.F. and Walther, G. (2012). Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales, J. Clin.
Microbiol., 50(1):66-75.
Sirisanthana, T. (2001). Penicillium marneffei Infection in Patients with AIDS, Emerging Inf. Dis., 7, 3. cited http://dx.doi.org/10.3201
/eid0707.017734.
Belet, N.; Ciftci, E.; Ince, E.; Dalgic, N.; Oncel, S.; Guriz, H.; Yagmurlu, A.; Dindar, H. andDogru, U. (2006). Caspofungin treatment in two
infants with persistent fungaemia due toCandida lipolytica. Scand J. Infect Dis., 38:559-562.
Odds, F.C.; Brown, A.J. and Gow, N.A. (2003).Antifungal agents: mechanisms of action. Trends Microbiol., 11:272-279.
Kucukates, E.; Erturan, Z.; Susever, S. and Yegenoglu, Y. (2005). In vitro susceptibility of yeasts isolated from patients in intensive care
units to fluconazole and amphotericin B during a 3-year period, APMIS, 113(4):278-283.
Girmenia, C.; Pizzarelli, G.; Cristini, F.;Barchiesi, F.; Spreghini, E.; Scalise, G. and Martino1, P. (2006). Candida guilliermondii
Fungemia in Patients with Hematologic Malignancies. J. Clin. Microbiol., 44(7):2458–2464.
Sabatelli, F.; Patel, R. and Mann, P. A. et al. (2006). In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and
amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother., 50:2009–2015.
Roxana, G.V.; de Hoog, G.S.; Schwarz, P.;Dannaoui, E.; Deng, S.; Machouart, M.; Voigt, K.; van de Sande, W.J.; Dolatabadi, S.; Meis,
J.F. and Walther, G. (2011). Antifungal susceptibility and phylogeny of opportunistic members of Mucorales. J. Clinical Microbiolo.,
:6111-6133.
Azor, M.; Gene, J.; Cano, J.; Sutton, D.A.;Fothergill, A.W.; Rinaldi, M.G. and Guarro, J. (2008). In Vitro Antifungal Susceptibility and
Molecular Characterization of Clinical Isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum, antimicrobial Agents
and Chemotherapy, 52:2228–2231.
Verweij, P.E.; Howard, S.J.; Melchers, W.J.; and Denning, D.W. (2007). Azole-resistance in Aspergillus: Proposed nomenclature and
breakpoints. Drug Resistance Updates, 12:141–147.
Bennett, J.E. (2011). Chapter 57. Antifungal Agents. In L.L. Brunton, B.A. Chabner, B.C. Knollmann (eds), Goodman and Gilman's The
Pharmacological Basis of Therapeutics, 12e. http://www. accessmedicine. com. ezp1. lib. umn. edu/content.